The 2026 biotechnology initial public offering (IPO) calendar has already featured plenty of familiar themes, particularly late-stage oncology and metabolic programs with relatively visible commercial opportunities. Electra Therapeutics is arriving with a different proposition.
The South San Francisco-based clinical-stage biotechnology company is developing antibody-based medicines for severe immune-mediated diseases and cancer. Its public-market debut will therefore be less about near-term revenue and more about whether its science can withstand the much less forgiving test of clinical development.
